OpSens to Be Acquired by Haemonetics

October 10, 2023—OpSens Inc. announces that it has entered into a definitive arrangement agreement with Haemonetics Corporation and 9500-7704 Québec Inc., a wholly-owned subsidiary of Haemonetics, whereby Haemonetics will indirectly acquire all issued and outstanding common shares in the capital of OpSens.

OpSens’ optical-based pressure guidewire aims to improve the clinical outcomes of patients with coronary artery disease. Haemonetics is a global health care company dedicated to providing a suite of innovative medical products and solutions. Haemonetics’ technology addresses blood and plasma component collection, the surgical suite, and hospital transfusion services.

According to OpSens, the transaction values the company at approximately Can$345 million, on a fully diluted equity basis.

OpSens’ board of directors unanimously approved the transaction and is recommending that its shareholders vote in favor of it. The transaction is expected to close by the end of January 2024, subject to the satisfaction of customary closing conditions. Upon closing of the transaction, OpSens shares will be delisted from the Toronto Stock Exchange, advised the company.

OpSens outlined the transaction’s benefits for the company and its stakeholders as follows:

• OpSens’ shareholders will receive a substantial premium to market price. Haemonetics’ offer of Can$2.90 per share in cash is a premium of 68% to OpSens’ 10-day volume-weighted average price and a premium of 50% to the closing price of Can$1.93 on the Toronto Stock Exchange as of October 6, 2023.
• Synergies between OpSens’ portfolio and Haemonetics’ hospital-based products will drive improvements in patient care.
• OpSens’ expertise in research & development and production coupled with Haemonetics’ commercial and manufacturing scale will drive the adoption of products globally. OpSens has developed substantial technical expertise and manufacturing capabilities, particularly as it relates to Fidela, OpSens’ second-generation fiber optic sensor.

OpSens’ flagship OptoWire is a second-generation fiber optic pressure guidewire that has been used in the diagnosis and treatment of more than 250,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan, and Canada.

The company’s SavvyWire for transcatheter aortic valve replacement procedures received FDA clearance and Health Canada approval in 2022.

These OpSens products provide synergies with Haemonetics’ products like the Vascade and Vascade MVP catheter-based vascular access-site closure devices used in interventional cardiology, electrophysiology, and peripheral vascular procedures, stated the company.